344 related articles for article (PubMed ID: 31174054)
1. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
[TBL] [Abstract][Full Text] [Related]
4. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
5. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
6. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
7. A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.
Bautista LE; Vera-Cala LM; Ferrante D; Herrera VM; Miranda JJ; Pichardo R; Sánchez Abanto JR; Ferreccio C; Silva E; Oróstegui Arenas M; Chirinos JA; Medina-Lezama J; Pérez CM; Schapochnik N; Casas JP
Health Aff (Millwood); 2013 Jan; 32(1):155-64. PubMed ID: 23297283
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
[TBL] [Abstract][Full Text] [Related]
10. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
Bramlage P; Sims H; Minguet J; Ferrero C
Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
[TBL] [Abstract][Full Text] [Related]
13. Polypill Strategy in Secondary Cardiovascular Prevention.
Castellano JM; Pocock SJ; Bhatt DL; Quesada AJ; Owen R; Fernandez-Ortiz A; Sanchez PL; Marin Ortuño F; Vazquez Rodriguez JM; Domingo-Fernández A; Lozano I; Roncaglioni MC; Baviera M; Foresta A; Ojeda-Fernandez L; Colivicchi F; Di Fusco SA; Doehner W; Meyer A; Schiele F; Ecarnot F; Linhart A; Lubanda JC; Barczi G; Merkely B; Ponikowski P; Kasprzak M; Fernandez Alvira JM; Andres V; Bueno H; Collier T; Van de Werf F; Perel P; Rodriguez-Manero M; Alonso Garcia A; Proietti M; Schoos MM; Simon T; Fernandez Ferro J; Lopez N; Beghi E; Bejot Y; Vivas D; Cordero A; Ibañez B; Fuster V;
N Engl J Med; 2022 Sep; 387(11):967-977. PubMed ID: 36018037
[TBL] [Abstract][Full Text] [Related]
14. An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial.
Laba TL; Hayes A; Lo S; Peiris DP; Usherwood T; Hillis GS; Rafter N; Reid CM; Tonkin AM; Webster R; Neal BC; Cass A; Patel A; Rodgers A; Jan S
Med J Aust; 2014 Dec; 201(11):671-3. PubMed ID: 25495315
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study.
Lin JK; Moran AE; Bibbins-Domingo K; Falase B; Pedroza Tobias A; Mandke CN; Kazi DS
Lancet Glob Health; 2019 Oct; 7(10):e1346-e1358. PubMed ID: 31477544
[TBL] [Abstract][Full Text] [Related]
16. Budget Impact of Appropriate Low-Dose Aspirin Use for Primary and Secondary Cardiovascular Event Prevention in the Managed Care Setting.
Carlton R; Coppolecchia R; Khalaf-Gillard K; Lennert B; Moradi A; Williamson T; Cameron J
J Manag Care Spec Pharm; 2018 Nov; 24(11):1102-1111. PubMed ID: 30362916
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of treatment and secondary prevention of acute myocardial infarction in India: a modeling study.
Megiddo I; Chatterjee S; Nandi A; Laxminarayan R
Glob Heart; 2014 Dec; 9(4):391-398.e3. PubMed ID: 25592792
[TBL] [Abstract][Full Text] [Related]
18. Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.
Ros-Castelló V; Natera-Villalba E; Gómez-López A; Sánchez-Sánchez A; Chico-García JL; García-Madrona S; Vera-Lechuga R; Matute-Lozano C; de Felipe Mimbrera A; Cruz-Culebras A; Alonso-Canovas A; Masjuan J
Cerebrovasc Dis Extra; 2020; 10(3):166-173. PubMed ID: 33176324
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain.
González-Domínguez A; Durán A; Hidalgo-Vega Á; Barrios V
Rev Clin Esp (Barc); 2023; 223(7):414-422. PubMed ID: 37352973
[TBL] [Abstract][Full Text] [Related]
20. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]